{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:38:09Z","timestamp":1773466689253,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.vaccine.2009.01.102","type":"journal-article","created":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T09:28:27Z","timestamp":1233480507000},"page":"1949-1956","source":"Crossref","is-referenced-by-count":76,"title":["Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20\u201338) peptide displayed on bacterial thioredoxin"],"prefix":"10.1016","volume":"27","author":[{"given":"Ivonne","family":"Rubio","sequence":"first","affiliation":[]},{"given":"Angelo","family":"Bolchi","sequence":"additional","affiliation":[]},{"given":"Nadia","family":"Moretto","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Canali","sequence":"additional","affiliation":[]},{"given":"Lutz","family":"Gissmann","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Tommasino","sequence":"additional","affiliation":[]},{"given":"Martin","family":"M\u00fcller","sequence":"additional","affiliation":[]},{"given":"Simone","family":"Ottonello","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.01.102_bib1","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrc1973","article-title":"How will HPV vaccines affect cervical cancer?","volume":"6","author":"Roden","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2009.01.102_bib2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1345\/aph.1G723","article-title":"Human papillomavirus vaccines","volume":"40","author":"Schmiedeskamp","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2009.01.102_bib3","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S1201-9712(07)60017-4","article-title":"Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine","volume":"11","author":"Villa","year":"2007","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2009.01.102_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1155\/2007\/939634","article-title":"A long way: history of the prophylactic papillomavirus vaccine","volume":"23","author":"Muller","year":"2007","journal-title":"Dis Markers"},{"key":"10.1016\/j.vaccine.2009.01.102_bib5","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.ygyno.2008.01.004","article-title":"The future of vaccines for cervical cancer","volume":"109","author":"Huh","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib6","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0264-410X(00)00370-4","article-title":"Immunological analyses of human papillomavirus capsids","volume":"19","author":"Giroglou","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.102_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/viro.1997.8649","article-title":"A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease","volume":"234","author":"Campo","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.01.102_bib8","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1128\/JVI.01577-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virol.2006.08.037","article-title":"Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region","volume":"358","author":"Kondo","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.01.102_bib10","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib11","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1128\/JVI.77.6.3531-3541.2003","article-title":"Cell surface-binding motifs of L2 that facilitate papillomavirus infection","volume":"77","author":"Yang","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib12","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.00143-08","article-title":"Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and l1 type-specific antibodies","volume":"82","author":"Day","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib13","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1128\/JVI.75.5.2331-2336.2001","article-title":"Human papillomavirus type 16 minor capsid protein L2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm","volume":"75","author":"Kawana","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib14","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0264-410X(00)00367-4","article-title":"Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies","volume":"19","author":"Kawana","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.102_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.virol.2005.04.011","article-title":"Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2","volume":"337","author":"Pastrana","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.01.102_bib16","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1128\/JVI.76.19.9798-9805.2002","article-title":"Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein","volume":"76","author":"Embers","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib17","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1073\/pnas.0800868105","article-title":"Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2","volume":"105","author":"Alphs","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2009.01.102_bib18","doi-asserted-by":"crossref","first-page":"11436","DOI":"10.1074\/jbc.M609690200","article-title":"Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide","volume":"282","author":"Moretto","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2009.01.102_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/cyto.1996.0002","article-title":"Expression and co-cytokine function of murine thioredoxin\/adult T cell leukaemia-derived factor (ADF)","volume":"8","author":"Blum","year":"1996","journal-title":"Cytokine"},{"key":"10.1016\/j.vaccine.2009.01.102_bib20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1084\/jem.189.11.1783","article-title":"Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells","volume":"189","author":"Bertini","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2009.01.102_bib21","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1110\/ps.04806004","article-title":"High-throughput automated refolding screening of inclusion bodies","volume":"13","author":"Vincentelli","year":"2004","journal-title":"Protein Sci"},{"key":"10.1016\/j.vaccine.2009.01.102_bib22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0009-9120(97)00049-0","article-title":"Removal of endotoxin from recombinant protein preparations","volume":"30","author":"Liu","year":"1997","journal-title":"Clin Biochem"},{"key":"10.1016\/j.vaccine.2009.01.102_bib23","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.2001.1220","article-title":"Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types","volume":"291","author":"Christensen","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.01.102_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1006\/viro.1996.0466","article-title":"Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies","volume":"223","author":"Christensen","year":"1996","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2009.01.102_bib25","doi-asserted-by":"crossref","first-page":"6480","DOI":"10.1128\/JVI.76.13.6480-6486.2002","article-title":"Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses","volume":"76","author":"Combita","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1099\/vir.0.83145-0","article-title":"Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types","volume":"89","author":"Rizk","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib27","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.4049\/jimmunol.167.3.1558","article-title":"DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines","volume":"167","author":"Rice","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib28","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1016\/S0264-410X(03)00454-7","article-title":"Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers","volume":"21","author":"Kawana","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.01.102_bib29","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/CVI.00164-07","article-title":"Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever","volume":"14","author":"Fraillery","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2009.01.102_bib30","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09001650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X09001650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T03:26:14Z","timestamp":1545449174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X09001650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0264410X09001650"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.01.102","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}